ARPA-H's $62.7M ADVOCATE program picks six teams to build the first FDA-authorized autonomous AI agent for heart-failure care
On Sept 9, 2026 ARPA-H named the teams for ADVOCATE, a four-year, $62.7M program ($33.7M in year one) to build what it calls the world's first FDA-authorized clinical agentic AI: patient-facing agents that can adjust heart-failure care (medications, appointments, diet, exercise) around the clock and call in clinicians when needed. Patient-facing teams must submit an FDA authorization package within 24 months. Forbes (Oct 3) reports that Anthropic has joined the initiative; its role is not stated in ARPA-H's materials.
Key facts
- Patient-facing agents (TA1): Atman Health (up to $7.7M), Tempus AI (up to $9.5M, extending its Olivia app), Updoc (up to $9.2M; says Microsoft, OpenAI and NVIDIA support its team)
- Supervisory AI (TA2): Stanford University, a disease-agnostic layer to catch unsafe recommendations; deployment (TA3): Duke University (testing across five health systems and rural sites) and Kaiser Permanente (21 medical centers, 260+ clinics); evaluator: Johns Hopkins APL
- Program manager: cardiologist Dr. Haider Warraich: 'a technology that can serve as a clinician-extender'
- TA1 teams must submit an FDA authorization package within 24 months of award; no generative/agentic AI has yet been FDA-authorized for clinical use, only predictive tools
- Anthropic: Forbes contributor Jesse Pines (Oct 3) writes that Anthropic joined the ARPA-H effort; ARPA-H's announcement does not name Anthropic, and no Anthropic statement was found (unverified role)
What happened
ARPA-H, the US health research agency, funded companies and health systems to build and test AI agents that act as a 24/7 member of a heart-failure care team, with a supervisory AI and real-world deployment at Kaiser Permanente and Duke, and the FDA involved from the start.
Why it matters
It is the first government program aimed squarely at getting an autonomous, patient-facing generative-AI agent through FDA authorization, so it may set the regulatory template for clinical agents. Anthropic's participation is reported only by Forbes so far.
Changelog
- 2026-10-05: created from the leads queue (Forbes, Oct 3); Forbes article not readable (403), Anthropic role taken from search summaries
Sources (6)
- officialARPA-H: launches the world's first bid to build FDA-authorized clinical AI for cardiovascular care (Sept 9, 2026)
- officialARPA-H: ADVOCATE program page
- officialARPA-H award: TEMPUS ADVOCATE
- pressMedTech Dive: ARPA-H to award $62.7M for AI in cardiovascular care
- pressAtman Health: wins ARPA-H award (PR Newswire)
- pressForbes (Jesse Pines): Anthropic is aiming to transform healthcare — here's how (Oct 3, 2026)
id: 2026-09-09-arpa-h-advocate-heart-failure-agents · updated 2026-10-05 · open in the interactive timeline